Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 25, 2021
Principal Executive Offices: Vancouver, B.C., Canada
Trading Symbol: ACHV (NASDAQ Capital Market)
This filing reports the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
Offering Structure:
- Shares to be Issued: 2,857,143 shares of common stock.
- Public Offering Price: $7.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 428,571 shares at the same price.
- Underwriter: Oppenheimer & Co., Inc. (as representative).
Estimated Proceeds:
- Net Proceeds: Approximately $18.5 million (after underwriting discounts, commissions, and estimated expenses).
- Assumption: Calculation assumes no exercise of the underwriters' option.
Use of Proceeds: Funding ongoing cytisinicline development, other clinical research and development, working capital, and general corporate purposes.
Liquidity and Debt: The filing text does not provide specific values for current cash balances, total debt, or liquidity ratios. It states proceeds will be used alongside existing cash, cash equivalents, and marketable securities.
Material Changes and Events
Material Definitive Agreement (Item 1.01): On May 25, 2021, the company entered into an underwriting agreement to sell the shares described above. The offering is expected to close on May 27, 2021, subject to customary closing conditions.
Other Events (Item 8.01):
- May 24, 2021: Press release announcing the commencement of the offering.
- May 25, 2021: Press release announcing the pricing of the offering.
Guidance, Outlook, and Risks
Management Commentary: Management intends to utilize the net proceeds to advance the development of cytisinicline and support general corporate operations.
Risks and Contingencies:
- The filing contains forward-looking statements regarding expected net proceeds and the use of proceeds.
- Actual results may differ materially due to risks identified in the company's Form 10-Q for the three months ended March 31, 2021, and the prospectus supplement.
- These risks could materially and adversely affect results of operations and stock price.
- The company disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the final closing date of the offering (expected May 27, 2021) and whether the underwriters exercised the 30-day option for additional shares.
- Confirm the actual net proceeds received after deducting all underwriting discounts and offering expenses.
- Review the prospectus supplement (referenced in the filing) for detailed risk factors specific to the offering.
- Check subsequent filings for updates on the allocation of proceeds to cytisinicline development versus general working capital.